Biolevate S.A.S. is a French life sciences software company that operates an evidence-grade AI platform for regulated operations. The platform links every claim, section, table, and recommendation to its supporting sources and documented rationale, with governed workflows, expert review checkpoints, and audit-ready run records. It serves pharmaceutical, medical device, cosmetics, and nutrition teams across clinical, regulatory, market access, and manufacturing workflows.
Biolevate is certified to ISO/IEC 27001 and 27701 and deploys in a private cloud or on-premises under GDPR requirements. Orange Ventures led its €30 million Series A announced in September 2026, after EQT Ventures led its €6 million seed round announced in November 2024. Its workflows include clinical protocol and CSR co-authoring, regulatory dossier co-authoring, safety signal surveillance, and systematic literature review.